Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia

Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sexton, Travis R., Zhang, Guoying, Macaulay, Tracy E., Callahan, Leigh A., Charnigo, Richard, Vsevolozhskaya, Olga A., Li, Zhenyu, Smyth, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
CLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115703/
https://www.ncbi.nlm.nih.gov/pubmed/30175268
http://dx.doi.org/10.1016/j.jacbts.2018.05.005
Descripción
Sumario:Despite treatment advances for sepsis and pneumonia, significant improvements in outcome have not been realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show that ticagrelor reduced leukocytes with attached platelets as well as the inflammatory biomarker interleukin (IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests trended toward improvement. Disruption of the P2Y(12) receptor in a murine model protected against inflammatory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets, leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to reduce complications.(Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor [XANTHIPPE]; NCT01883869)

Ejemplares similares